GCM
BVS icon

Gladius Capital Management’s Bioventus BVS Stock Holding History

Gladius Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,773
Closed -$40.4K – 313
2024
Q1 		$40.4K Buy
+7,773
New +$38K 0.01% 207
2023
Q3 		– Sell
-11,002
Closed -$31.8K – 387
2023
Q2 		$31.8K Sell
11,002
-7,699
-41% -$14.8K ﹤0.01% 248
2023
Q1 		$20K Buy
18,701
+262
+1% +$501 ﹤0.01% 320
2022
Q4 		$48.1K Buy
+18,439
New +$80.5K ﹤0.01% 201

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Gladius Capital Management's BVS Position: Q2 2024 in Review

Gladius Capital Management sold out of Bioventus (BVS) in Q2 2024, closing a stake of 7,773 shares — an estimated $40.4K sold.

Gladius Capital Management first reported a position in BVS in Q4 2022 and held it in 4 quarters. The position peaked at $48.1K in Q4 2022. 103 funds tracked by Wall St. Rank hold BVS as of Q2 2024.

  • Gladius Capital Management reported no remaining Bioventus position as of Q2 2024 after selling out during the quarter.
  • Gladius Capital Management sold 7,773 Bioventus shares in Q2 2024, an estimated $40.4K.
  • Gladius Capital Management first reported a position in Bioventus in Q4 2022 and held it in 4 quarters.
  • Gladius Capital Management's Bioventus position peaked at $48.1K in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Bioventus as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.